Is Wall Street Bullish or Bearish on Bio-Techne Stock?

Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $11.3 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.

Shares of this leading life sciences reagents and instruments company have outperformed the broader market over the past year. TECH has gained 35.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.1%. In 2026, TECH stock is up 23.1%, surpassing the SPX’s 13.1% rise on a YTD basis. 

Narrowing the focus, TECH’s underperformance is apparent compared to the iShares Biotechnology ETF’s (IBB). The exchange-traded fund has gained about 45.5% over the past year. However, TECH’s gains on a YTD basis outshine the ETF’s 19.7% returns over the same time frame.

TECH delivered mixed financial results, characterized by steady bottom-line net income growth alongside sluggish top-line revenue expansion. Sluggish biotech funding environment and uneven biopharma demand kept full-year sales mostly flat at $1.2 billion, while organic growth struggled to gain substantial traction across core instrument and diagnostic lines. However, disciplined cost controls, operational efficiencies, and targeted divestitures substantially improved GAAP operating margins and year over year net earnings. This operational resilience, coupled with an agreement to be acquired by Merck KGaA (MKGAF) helped support investor sentiment and spark a strong stock rally heading into late 2026 despite persistent top-line macro headwinds.  

On Aug. 12, TECH shares closed up marginally after reporting its Q4 results. Its adjusted EPS of $0.52 met Wall Street expectations. The company’s revenue was $321.2 million, topping Wall Street forecasts of $317.2 million.

For fiscal 2027, ending in June 2027, analysts expect TECH’s EPS to grow 2.3% to $1.76 on a diluted basis. The company’s earnings surprise history is impressive. It beat or matched the consensus estimate in each of the last four quarters.

Among the 15 analysts covering TECH stock, the consensus is a “Hold.” That’s based on one “Strong Buy” rating, 13 “Holds,” and one “Strong Sell.”

This configuration is less bullish than a month ago, with two analysts suggesting a “Strong Buy.”

On Aug. 17, Wells Fargo & Company (WFC) downgraded TECH to an “Equal Weight” rating with a $73 price target, the Street-high price target, implying a marginal potential upside from current levels.

TECH currently trades above its mean price target of $70.46, reflecting market optimism.